A phase I dose escalation study of Upamostat in Chinese patients with solid tumour
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Upamostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 17 Jan 2016 New trial record
- 13 Jan 2016 According to a Wiles AG media release, the company announced that Link Health Co. submitted an IND application to the CFDA (China Food and Drug Administration) of Mesupron (Upamostat) for the treatment of solid tumour.